Holen Sie sich die Stockscreener-App
33.56
0.33%
-0.13
Schlusskurs vom Vortag:
$33.69
Offen:
$34.38
24-Stunden-Volumen:
51,220
Relative Volume:
0.52
Marktkapitalisierung:
$2.21B
Einnahmen:
$282.04M
Nettoeinkommen (Verlust:
$221.88M
KGV:
9.9709
EPS:
3.3658
Netto-Cashflow:
$-449.57M
1W Leistung:
+0.27%
1M Leistung:
+0.60%
6M Leistung:
+0.66%
1J Leistung:
+28.86%
1-Tages-Spanne:
$33.34
$34.42
1-Wochen-Bereich:
$32.45
$34.42
52-Wochen-Spanne:
$22.59
$37.78
Galapagos Nv Adr Stock (GLPG) Company Profile
Firmenname
Galapagos Nv Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare GLPG vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLPG
Galapagos Nv Adr
|
33.59 | 2.22B | 282.04M | 221.88M | -449.57M | 3.3658 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.95 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
769.92 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
727.60 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.09 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.77 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-02-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-11-20 | Herabstufung | Kepler | Hold → Reduce |
| 2024-09-09 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-08-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-03-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-08-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-01-23 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-11-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-19 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-08-06 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-04-20 | Eingeleitet | Deutsche Bank | Buy |
| 2021-04-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-02-19 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-02-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-19 | Eingeleitet | Maxim Group | Buy |
| 2020-10-21 | Herabstufung | Goldman | Neutral → Sell |
| 2020-08-25 | Herabstufung | Jefferies | Buy → Hold |
| 2020-08-24 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-08-19 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-08-19 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-07-10 | Herabstufung | Stifel | Buy → Hold |
| 2020-03-30 | Hochstufung | Jefferies | Hold → Buy |
| 2020-03-18 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2020-02-25 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-02-24 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-01-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-12-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-12-02 | Eingeleitet | BofA/Merrill | Neutral |
| 2019-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-07-31 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-29 | Herabstufung | Jefferies | Buy → Hold |
Alle ansehen
Galapagos Nv Adr Aktie (GLPG) Neueste Nachrichten
Galapagos FY 2025 slides: €3B cash fuels transformation strategy - Investing.com Australia
RBC Capital raises Galapagos stock price target to $33 on model updates - Investing.com South Africa
Earnings call transcript: Galapagos Q4 2025 earnings surpass expectations, stock rises By Investing.com - Investing.com South Africa
Galapagos stock rating reiterated at Market Perform by Raymond James - Investing.com
Galapagos FY 2025 slides: €3B cash fuels transformation strategy By Investing.com - Investing.com South Africa
Earnings call transcript: Galapagos Q4 2025 earnings surpass expectations, stock rises - Investing.com
Earnings Breakdown: Galapagos Q4 - Sahm
A Peek at Galapagos's Future Earnings - Sahm
Stock Market Today: Nasdaq Futures Pare Losses, Dow Drops After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus (UPDATED) - Benzinga
Stock Market Today: Nasdaq Futures Pare Losses, Dow Drops After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus (UPDATED) - Benzinga
Stock Market Today: Dow Jones Futures Drop After Scaling Record Highs— CoreWeave, Vistra, Microchip Technology In Focus - Sahm
AngioDynamics, Microchip Technology And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Galapagos NV (NASDAQ:GLPG) Given Average Rating of “Reduce” by Analysts - Defense World
Galapagos stock holds steady as Raymond James maintains Market Perform rating By Investing.com - Investing.com South Africa
Galapagos stock holds steady as Raymond James maintains Market Perform rating - Investing.com
Bernstein initiates Market Perform rating on Galapagos stock with EUR27.90 target - Investing.com
Galapagos NV (GLPG) Stock Price, Trades & News - GuruFocus
Operating cash flow per share of Galapagos NV Sponsored ADR – NASDAQ:GLPG - TradingView
Working capital per share of Galapagos NV Sponsored ADR – NASDAQ:GLPG - TradingView
Galapagos NV (NASDAQ:GLPG) Receives Average Rating of “Reduce” from Analysts - Defense World
EBIT per share of Galapagos NV Sponsored ADR – NASDAQ:GLPG - TradingView
Earnings call transcript: Galapagos Q3 2025 sees earnings miss, stock steady By Investing.com - Investing.com Canada
Earnings call transcript: Galapagos Q3 2025 sees earnings miss, stock steady - Investing.com
Galapagos stock price target raised to $28 from $27 at RBC Capital - Investing.com
Galapagos stock rating upgraded by Leerink Partners on cost-cutting moves - Investing.com
PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Galapagos Appoints Fred Blakeslee as General Counsel - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), Pharvaris (PHVS) and Stevanato Group (STVN) - The Globe and Mail
How Have Insiders Been Trading Winmark Corporation (WINA) Stock? - fostersleader.com
Why You Need Galapagos NV ADR (GLPG) On Your Watchlist - fostersleader.com
Stock on Demand This Week: Hour Loop Inc (HOUR) - fostersleader.com
MasterCraft Boat Holdings Inc (MCFT): What the Financials Tell Us - fostersleader.com
Is Buying Stock In Radiopharm Theranostics Ltd ADR (RADX) A Good Move Today? - fostersleader.com
Major Brokerage Firms Issue Research Notes on Surgepays Inc (SURG) - fostersleader.com
Vishay Precision Group Inc (VPG) Shares: Cheap or Risky? - fostersleader.com
Clene Inc (CLNN): What Technical Indicators Show - fostersleader.com
SolarMax Technology Inc (SMXT): What Does Valuation Ratios Tell Us? - fostersleader.com
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? - TechStock²
Galapagos Updates on Cell Therapy Business Strategic Review - The Globe and Mail
Galapagos NV (GLPG)' CAR-T Therapy Hits 97% Response Rate in Lymphoma Trial - Finviz
Galapagos (0JXZ) was downgraded to a Sell Rating at Deutsche Bank - The Globe and Mail
Galapagos NV Reports Strong H1 2025 Results Amid Strategic Transformation - The Globe and Mail
Raymond James reiterates Market Perform rating on Galapagos stock - Investing.com
Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com
Galapagos stock holds as CEO change, spinoff plans halted - Investing.com
Galapagos stock holds Market Perform rating at Raymond James - Investing.com
Galapagos To Spin Off Innovative Medicines Business - Forbes
Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com
Earnings call: Galapagos focuses on oncology and immunology in H1 2024 report - Investing.com
Galapagos NV shares poised for outperformance, says TD Cowen - Investing.com
Finanzdaten der Galapagos Nv Adr-Aktie (GLPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):